Status:
COMPLETED
The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer
Lead Sponsor:
University Clinical Centre of Kosova
Conditions:
Breast Cancer Invasive
Eligibility:
FEMALE
20-70 years
Brief Summary
The aim of this study has been to explore whether there is any elevation of Interleukin-7 serum level in the early invasive breast cancer (EIBC) patients in comparison with healthy controls. In additi...
Detailed Description
This cross-sectional, observational, and analytical study has been undertaken in the Clinic of Oncology, University Hospital Center Zagreb, Croatia, and the Department of Thoracic Surgery in the Unive...
Eligibility Criteria
Inclusion
- Patients with invasive breast cancer, confirmed with biopsy
- Operable and without distant metastases.
Exclusion
- Patients with acute and/or chronic inflammatory diseases, rheumatoid disease and other malignancies occurring simultaneously
- Patients receiving immune modulatory therapy
- Patients previously treated by surgery, chemotherapy, radiotherapy, target therapy or endocrine therapy
- Patients with dementia or any other psychological disorders unable to willingly participate in the study.
- Exclusion Criteria for the control group:
- Breast tumors or any other confirmed malignancies
- Any acute or chronic inflammatory disease
- Receiving immune modulatory therapy
Key Trial Info
Start Date :
June 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 20 2019
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT05300412
Start Date
June 5 2018
End Date
December 20 2019
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faton I. Sermaxhaj, MD
Pristina, Kosovo, 10000